3D Medicines (HKSE:01244) Net Margin % : -122.60% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. 3D Medicines's Net Income for the six months ended in Dec. 2023 was HK$-378.7 Mil. 3D Medicines's Revenue for the six months ended in Dec. 2023 was HK$308.9 Mil. Therefore, 3D Medicines's net margin for the quarter that ended in Dec. 2023 was -122.60%.

The historical rank and industry rank for 3D Medicines's Net Margin % or its related term are showing as below:

HKSE:01244' s Net Margin % Range Over the Past 10 Years
Min: -2379.85 Med: -180.54 Max: -82.64
Current: -82.64

HKSE:01244's Net Margin % is ranked better than
56.53% of 1033 companies
in the Biotechnology industry
Industry Median: -162.58 vs HKSE:01244: -82.64

3D Medicines Net Margin % Historical Data

The historical data trend for 3D Medicines's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Net Margin % Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

-2,379.85

-180.54

-82.64

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial			-	-148.99	-198.66	-50.63	-122.60

Competitive Comparison of 3D Medicines's Net Margin %

For the Biotechnology subindustry, 3D Medicines's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3D Medicines's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Net Margin % distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Net Margin % falls into.

3D Medicines Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

3D Medicines's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-573.903	/	694.494
	=	-82.64 %

3D Medicines's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-378.679	/	308.879
	=	-122.60 %

3D Medicines (HKSE:01244) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

3D Medicines Net Margin % Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

3D Medicines (HKSE:01244) Headlines

No Headlines